Unlocking RBness: expanding TNBC treatment options beyond RB1 mutations

In this interview, we speak with Syed Haider and Chris Lord (both from The Institute of Cancer Research, London, UK) about their work on the RB1 tumor suppressor gene, which plays a key role in cancer development - including in about 13% of triple negative breast cancers (TNBC). They introduce the concept of RBness and how their findings may expand treatment options for both TNBC patients and other RBness cancers. Can you explain the concept of RBness and how it relates to cancer treatment? Cancer patients are often grouped, treated and studied by the presence and absence of changes or...